Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 503


A novel hotspot specific isothermal amplification method for detection of the common PIK3CA p.H1047R breast cancer mutation.

Kalofonou M, Malpartida-Cardenas K, Alexandrou G, Rodriguez-Manzano J, Yu LS, Miscourides N, Allsopp R, Gleason KLT, Goddard K, Fernandez-Garcia D, Page K, Georgiou P, Ali S, Coombes RC, Shaw J, Toumazou C.

Sci Rep. 2020 Mar 12;10(1):4553. doi: 10.1038/s41598-020-60852-3.


Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer.

Fernandez-Garcia D, Hills A, Page K, Hastings RK, Toghill B, Goddard KS, Ion C, Ogle O, Boydell AR, Gleason K, Rutherford M, Lim A, Guttery DS, Coombes RC, Shaw JA.

Breast Cancer Res. 2019 Dec 19;21(1):149. doi: 10.1186/s13058-019-1235-8.


Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy.

Hong SP, Chan TE, Lombardo Y, Corleone G, Rotmensz N, Bravaccini S, Rocca A, Pruneri G, McEwen KR, Coombes RC, Barozzi I, Magnani L.

Nat Commun. 2019 Sep 2;10(1):3840. doi: 10.1038/s41467-019-11721-9.


Author Correction: Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion.

Nguyen VTM, Barozzi I, Faronato M, Lombardo Y, Steel JH, Patel N, Darbre P, Castellano L, Győrffy B, Woodley L, Rodriguez-Meira A, Patten DK, Vircillo V, Periyasamy M, Ali S, Frige G, Minucci S, Coombes RC, Magnani L.

Nat Commun. 2019 Aug 6;10(1):3505. doi: 10.1038/s41467-019-11569-z.


Frizzled-7-targeted delivery of zinc oxide nanoparticles to drug-resistant breast cancer cells.

Ruenraroengsak P, Kiryushko D, Theodorou IG, Klosowski MM, Taylor ER, Niriella T, Palmieri C, Yagüe E, Ryan MP, Coombes RC, Xie F, Porter AE.

Nanoscale. 2019 Jul 11;11(27):12858-12870. doi: 10.1039/c9nr01277j.


Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence.

Coombes RC, Page K, Salari R, Hastings RK, Armstrong A, Ahmed S, Ali S, Cleator S, Kenny L, Stebbing J, Rutherford M, Sethi H, Boydell A, Swenerton R, Fernandez-Garcia D, Gleason KLT, Goddard K, Guttery DS, Assaf ZJ, Wu HT, Natarajan P, Moore DA, Primrose L, Dashner S, Tin AS, Balcioglu M, Srinivasan R, Shchegrova SV, Olson A, Hafez D, Billings P, Aleshin A, Rehman F, Toghill BJ, Hills A, Louie MC, Lin CJ, Zimmermann BG, Shaw JA.

Clin Cancer Res. 2019 Jul 15;25(14):4255-4263. doi: 10.1158/1078-0432.CCR-18-3663. Epub 2019 Apr 16.


Oncogenic EP300 can be targeted with inhibitors of aldo-keto reductases.

Mahmud Z, Asaduzzaman M, Kumar U, Masrour N, Jugov R, Coombes RC, Shousha S, Hu Y, Lam EW, Yagüe E.

Biochem Pharmacol. 2019 May;163:391-403. doi: 10.1016/j.bcp.2019.03.009. Epub 2019 Mar 9.


Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES.

Szijgyarto Z, Flach KD, Opdam M, Palmieri C, Linn SC, Wesseling J, Ali S, Bliss JM, Cheang MCU, Zwart W, Coombes RC.

Breast Cancer Res Treat. 2019 May;175(1):149-163. doi: 10.1007/s10549-018-05110-x. Epub 2019 Jan 24.


Towards multiplexed near-infrared cellular imaging using gold nanostar arrays with tunable fluorescence enhancement.

Theodorou IG, Ruenraroengsak P, Gonzalez-Carter DA, Jiang Q, Yagüe E, Aboagye EO, Coombes RC, Porter AE, Ryan MP, Xie F.

Nanoscale. 2019 Jan 23;11(4):2079-2088. doi: 10.1039/c8nr09409h.


A framework for the development of effective anti-metastatic agents.

Anderson RL, Balasas T, Callaghan J, Coombes RC, Evans J, Hall JA, Kinrade S, Jones D, Jones PS, Jones R, Marshall JF, Panico MB, Shaw JA, Steeg PS, Sullivan M, Tong W, Westwell AD, Ritchie JWA; Cancer Research UK and Cancer Therapeutics CRC Australia Metastasis Working Group.

Nat Rev Clin Oncol. 2019 Mar;16(3):185-204. doi: 10.1038/s41571-018-0134-8.


Clinical translation of [18F]ICMT-11 for measuring chemotherapy-induced caspase 3/7 activation in breast and lung cancer.

Dubash SR, Merchant S, Heinzmann K, Mauri F, Lavdas I, Inglese M, Kozlowski K, Rama N, Masrour N, Steel JF, Thornton A, Lim AK, Lewanski C, Cleator S, Coombes RC, Kenny L, Aboagye EO.

Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2285-2299. doi: 10.1007/s00259-018-4098-9. Epub 2018 Sep 27.


Fluorescence enhancement from single gold nanostars: towards ultra-bright emission in the first and second near-infrared biological windows.

Theodorou IG, Jiang Q, Malms L, Xie X, Coombes RC, Aboagye EO, Porter AE, Ryan MP, Xie F.

Nanoscale. 2018 Aug 23;10(33):15854-15864. doi: 10.1039/c8nr04567d.


Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer.

Patten DK, Corleone G, Győrffy B, Perone Y, Slaven N, Barozzi I, Erdős E, Saiakhova A, Goddard K, Vingiani A, Shousha S, Pongor LS, Hadjiminas DJ, Schiavon G, Barry P, Palmieri C, Coombes RC, Scacheri P, Pruneri G, Magnani L.

Nat Med. 2018 Sep;24(9):1469-1480. doi: 10.1038/s41591-018-0091-x. Epub 2018 Jul 23.


Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer.

Blok EJ, Engels CC, Dekker-Ensink G, Meershoek-Klein Kranenbarg E, Putter H, Smit VTHBM, Liefers GJ, Morden JP, Bliss JM, Coombes RC, Bartlett JMS, Kroep JR, van de Velde CJH, Kuppen PJK.

Breast Cancer Res Treat. 2018 Aug;171(1):65-74. doi: 10.1007/s10549-018-4785-z. Epub 2018 May 15.


ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment.

Patel H, Periyasamy M, Sava GP, Bondke A, Slafer BW, Kroll SHB, Barbazanges M, Starkey R, Ottaviani S, Harrod A, Aboagye EO, Buluwela L, Fuchter MJ, Barrett AGM, Coombes RC, Ali S.

Mol Cancer Ther. 2018 Jun;17(6):1156-1166. doi: 10.1158/1535-7163.MCT-16-0847. Epub 2018 Mar 15.


Corrigendum: Inhibitor Selectivity for Cyclin-Dependent Kinase 7: A Structural, Thermodynamic, and Modelling Study.

Hazel P, Kroll SHB, Bondke A, Barbazanges M, Patel H, Fuchter MJ, Coombes RC, Ali S, Barrett AGM, Freemont PS.

ChemMedChem. 2018 Jan 22;13(2):207. doi: 10.1002/cmdc.201700826. Epub 2018 Jan 16. No abstract available.


Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES.

Cheang MCU, Bliss JM, Viale G, Speirs V, Palmieri C, Shaaban A, Lønning PE, Morden J, Porta N, Jassem J, van De Velde CJ, Rasmussen BB, Verhoeven D, Bartlett JMS, Coombes RC; PathIES Sub-Committee.

Breast Cancer Res Treat. 2018 Feb;168(1):169-178. doi: 10.1007/s10549-017-4543-7. Epub 2017 Nov 24.


p53 controls expression of the DNA deaminase APOBEC3B to limit its potential mutagenic activity in cancer cells.

Periyasamy M, Singh AK, Gemma C, Kranjec C, Farzan R, Leach DA, Navaratnam N, Pálinkás HL, Vértessy BG, Fenton TR, Doorbar J, Fuller-Pace F, Meek DW, Coombes RC, Buluwela L, Ali S.

Nucleic Acids Res. 2017 Nov 2;45(19):11056-11069. doi: 10.1093/nar/gkx721.


Erratum to: Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer.

Saleem A, Searle GE, Kenny LM, Huiban M, Kozlowski K, Waldman AD, Woodley L, Palmieri C, Lowdell C, Kaneko T, Murphy PS, Lau MR, Aboagye EO, Coombes RC.

EJNMMI Res. 2017 Sep 8;7(1):74. doi: 10.1186/s13550-017-0323-y. No abstract available.


IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer.

Palmieri C, Szydlo R, Miller M, Barker L, Patel NH, Sasano H, Barwick T, Tam H, Hadjiminas D, Lee J, Shaaban A, Nicholas H, Coombes RC, Kenny LM.

Breast Cancer Res Treat. 2017 Nov;166(2):527-539. doi: 10.1007/s10549-017-4427-x. Epub 2017 Aug 9.


IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients.

Palmieri C, Stein RC, Liu X, Hudson E, Nicholas H, Sasano H, Guestini F, Holcombe C, Barrett S, Kenny L, Reed S, Lim A, Hayward L, Howell S, Coombes RC; IRIS trial participants.

Breast Cancer Res Treat. 2017 Sep;165(2):343-353. doi: 10.1007/s10549-017-4328-z. Epub 2017 Jun 13. Erratum in: Breast Cancer Res Treat. 2018 Jan;167(1):407.


NY-ESO-1 expression in DCIS: A new predictor of good prognosis.

Coombes RC, Caballero OL, Shousha S, Ghaem-Maghami S, Woodley-Barker L, Wilhelm-Benartzi CS, Neville AM.

Oncoscience. 2017 Apr 28;4(3-4):33-40. doi: 10.18632/oncoscience.348. eCollection 2017 Mar.


Long-Term Follow-Up of the Intergroup Exemestane Study.

Morden JP, Alvarez I, Bertelli G, Coates AS, Coleman R, Fallowfield L, Jassem J, Jones S, Kilburn L, Lønning PE, Ortmann O, Snowdon C, van de Velde C, Andersen J, Del Mastro L, Dodwell D, Holmberg S, Nicholas H, Paridaens R, Bliss JM, Coombes RC.

J Clin Oncol. 2017 Aug 1;35(22):2507-2514. doi: 10.1200/JCO.2016.70.5640. Epub 2017 May 3.


Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer.

Asaduzzaman M, Constantinou S, Min H, Gallon J, Lin ML, Singh P, Raguz S, Ali S, Shousha S, Coombes RC, Lam EW, Hu Y, Yagüe E.

Breast Cancer Res Treat. 2017 Jun;163(3):461-474. doi: 10.1007/s10549-017-4202-z. Epub 2017 Mar 24. Erratum in: Breast Cancer Res Treat. 2018 Jan 5;:.


Inhibitor Selectivity for Cyclin-Dependent Kinase 7: A Structural, Thermodynamic, and Modelling Study.

Hazel P, Kroll SH, Bondke A, Barbazanges M, Patel H, Fuchter MJ, Coombes RC, Ali S, Barrett AG, Freemont PS.

ChemMedChem. 2017 Mar 7;12(5):372-380. doi: 10.1002/cmdc.201600535. Epub 2017 Feb 6. Erratum in: ChemMedChem. 2018 Jan 22;13(2):207.


Next Generation Sequencing of Circulating Cell-Free DNA for Evaluating Mutations and Gene Amplification in Metastatic Breast Cancer.

Page K, Guttery DS, Fernandez-Garcia D, Hills A, Hastings RK, Luo J, Goddard K, Shahin V, Woodley-Barker L, Rosales BM, Coombes RC, Stebbing J, Shaw JA.

Clin Chem. 2017 Feb;63(2):532-541. doi: 10.1373/clinchem.2016.261834. Epub 2016 Dec 9.


Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts.

Shaw JA, Guttery DS, Hills A, Fernandez-Garcia D, Page K, Rosales BM, Goddard KS, Hastings RK, Luo J, Ogle O, Woodley L, Ali S, Stebbing J, Coombes RC.

Clin Cancer Res. 2017 Jan 1;23(1):88-96. doi: 10.1158/1078-0432.CCR-16-0825. Epub 2016 Jun 22.


Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptor-Positive Breast Cancer.

Patel H, Abduljabbar R, Lai CF, Periyasamy M, Harrod A, Gemma C, Steel JH, Patel N, Busonero C, Jerjees D, Remenyi J, Smith S, Gomm JJ, Magnani L, Győrffy B, Jones LJ, Fuller-Pace F, Shousha S, Buluwela L, Rakha EA, Ellis IO, Coombes RC, Ali S.

Clin Cancer Res. 2016 Dec 1;22(23):5929-5938. Epub 2016 Jun 14.


Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer.

Harrod A, Fulton J, Nguyen VTM, Periyasamy M, Ramos-Garcia L, Lai CF, Metodieva G, de Giorgio A, Williams RL, Santos DB, Gomez PJ, Lin ML, Metodiev MV, Stebbing J, Castellano L, Magnani L, Coombes RC, Buluwela L, Ali S.

Oncogene. 2017 Apr 20;36(16):2286-2296. doi: 10.1038/onc.2016.382. Epub 2016 Oct 17.


Stratified, precision or personalised medicine? Cancer services in the 'real world' of a London hospital.

Day S, Coombes RC, McGrath-Lone L, Schoenborn C, Ward H.

Sociol Health Illn. 2017 Jan;39(1):143-158. doi: 10.1111/1467-9566.12457. Epub 2016 Jul 27.


Epirubicin dose and sequential hormonal therapy-Mature results of the HMFEC randomised phase III trial in premenopausal patients with node positive early breast cancer.

Coombes RC, Kilburn LS, Tubiana-Mathieu N, Olmos T, Van Bochove A, Perez-Lopez FR, Palmieri C, Stebbing J, Bliss JM.

Eur J Cancer. 2016 Jun;60:146-53. doi: 10.1016/j.ejca.2016.03.001. Epub 2016 Apr 26.


New IR imaging modalities for cancer detection and for intra-cell chemical mapping with a sub-diffraction mid-IR s-SNOM.

Amrania H, Drummond L, Coombes RC, Shousha S, Woodley-Barker L, Weir K, Hart W, Carter I, Phillips CC.

Faraday Discuss. 2016 Jun 23;187:539-53. doi: 10.1039/c5fd00150a.


Spearhead Nanometric Field-Effect Transistor Sensors for Single-Cell Analysis.

Zhang Y, Clausmeyer J, Babakinejad B, Córdoba AL, Ali T, Shevchuk A, Takahashi Y, Novak P, Edwards C, Lab M, Gopal S, Chiappini C, Anand U, Magnani L, Coombes RC, Gorelik J, Matsue T, Schuhmann W, Klenerman D, Sviderskaya EV, Korchev Y.

ACS Nano. 2016 Mar 22;10(3):3214-3221. doi: 10.1021/acsnano.5b05211. Epub 2016 Feb 1.


Bone marrow micrometastases in early breast cancer-30-year outcome.

Mansi J, Morden J, Bliss JM, Neville M, Coombes RC.

Br J Cancer. 2016 Feb 2;114(3):243-7. doi: 10.1038/bjc.2015.447. Epub 2016 Jan 14.


Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion.

Nguyen VT, Barozzi I, Faronato M, Lombardo Y, Steel JH, Patel N, Darbre P, Castellano L, Győrffy B, Woodley L, Meira A, Patten DK, Vircillo V, Periyasamy M, Ali S, Frige G, Minucci S, Coombes RC, Magnani L.

Nat Commun. 2015 Nov 27;6:10044. doi: 10.1038/ncomms10044. Erratum in: Nat Commun. 2019 Aug 6;10(1):3505.


MiR-106b~25 cluster regulates multidrug resistance in an ABC transporter-independent manner via downregulation of EP300.

Hu Y, Li K, Asaduzzaman M, Cuella R, Shi H, Raguz S, Coombes RC, Zhou Y, Yagüe E.

Oncol Rep. 2016 Feb;35(2):1170-8. doi: 10.3892/or.2015.4412. Epub 2015 Nov 12.


APOBEC3B-Mediated Cytidine Deamination Is Required for Estrogen Receptor Action in Breast Cancer.

Periyasamy M, Patel H, Lai CF, Nguyen VTM, Nevedomskaya E, Harrod A, Russell R, Remenyi J, Ochocka AM, Thomas RS, Fuller-Pace F, Győrffy B, Caldas C, Navaratnam N, Carroll JS, Zwart W, Coombes RC, Magnani L, Buluwela L, Ali S.

Cell Rep. 2015 Oct 6;13(1):108-121. doi: 10.1016/j.celrep.2015.08.066. Epub 2015 Sep 24.


SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer.

Zwart W, Flach KD, Rudraraju B, Abdel-Fatah TM, Gojis O, Canisius S, Moore D, Nevedomskaya E, Opdam M, Droog M, Hofland I, Chan S, Shaw J, Ellis IO, Coombes RC, Carroll JS, Ali S, Palmieri C.

Clin Cancer Res. 2016 Jan 15;22(2):479-91. doi: 10.1158/1078-0432.CCR-14-3277. Epub 2015 Sep 14.


Expression profiling of nuclear receptors in breast cancer identifies TLX as a mediator of growth and invasion in triple-negative breast cancer.

Lin ML, Patel H, Remenyi J, Banerji CR, Lai CF, Periyasamy M, Lombardo Y, Busonero C, Ottaviani S, Passey A, Quinlan PR, Purdie CA, Jordan LB, Thompson AM, Finn RS, Rueda OM, Caldas C, Gil J, Coombes RC, Fuller-Pace FV, Teschendorff AE, Buluwela L, Ali S.

Oncotarget. 2015 Aug 28;6(25):21685-703.


The pioneer factor PBX1 is a novel driver of metastatic progression in ERα-positive breast cancer.

Magnani L, Patten DK, Nguyen VT, Hong SP, Steel JH, Patel N, Lombardo Y, Faronato M, Gomes AR, Woodley L, Page K, Guttery D, Primrose L, Fernandez Garcia D, Shaw J, Viola P, Green A, Nolan C, Ellis IO, Rakha EA, Shousha S, Lam EW, Győrffy B, Lupien M, Coombes RC.

Oncotarget. 2015 Sep 8;6(26):21878-91.


DMXL2 drives epithelial to mesenchymal transition in hormonal therapy resistant breast cancer through Notch hyper-activation.

Faronato M, Nguyen VT, Patten DK, Lombardo Y, Steel JH, Patel N, Woodley L, Shousha S, Pruneri G, Coombes RC, Magnani L.

Oncotarget. 2015 Sep 8;6(26):22467-79.


Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)-first results from PathIES†.

Speirs V, Viale G, Mousa K, Palmieri C, Reed SN, Nicholas H, Cheang M, Jassem J, Lønning PE, Kalaitzaki E, van de Velde CJ, Rasmussen BB, Verhoeven DM, Shaaban AM, Bartlett JM, Bliss JM, Coombes RC; PathIES Sub-Committee.

Ann Oncol. 2015 Sep;26(9):1890-7. doi: 10.1093/annonc/mdv242. Epub 2015 May 22.


Apoptosis inhibitor TRIAP1 is a novel effector of drug resistance.

Adams C, Cazzanelli G, Rasul S, Hitchinson B, Hu Y, Coombes RC, Raguz S, Yagüe E.

Oncol Rep. 2015 Jul;34(1):415-22. doi: 10.3892/or.2015.3988. Epub 2015 May 19.


Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer.

Guttery DS, Page K, Hills A, Woodley L, Marchese SD, Rghebi B, Hastings RK, Luo J, Pringle JH, Stebbing J, Coombes RC, Ali S, Shaw JA.

Clin Chem. 2015 Jul;61(7):974-82. doi: 10.1373/clinchem.2015.238717. Epub 2015 May 15.


Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer.

Saleem A, Searle GE, Kenny LM, Huiban M, Kozlowski K, Waldman AD, Woodley L, Palmieri C, Lowdell C, Kaneko T, Murphy PS, Lau MR, Aboagye EO, Coombes RC.

EJNMMI Res. 2015 Apr 30;5:30. doi: 10.1186/s13550-015-0103-5. eCollection 2015. Erratum in: EJNMMI Res. 2017 Sep 8;7(1):74. EJNMMI Res. 2017 Sep 18;7(1):76.


Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance.

Khongkow P, Gomes AR, Gong C, Man EP, Tsang JW, Zhao F, Monteiro LJ, Coombes RC, Medema RH, Khoo US, Lam EW.

Oncogene. 2016 Feb 25;35(8):990-1002. doi: 10.1038/onc.2015.152. Epub 2015 May 11.


Myocardial MiR-30 downregulation triggered by doxorubicin drives alterations in β-adrenergic signaling and enhances apoptosis.

Roca-Alonso L, Castellano L, Mills A, Dabrowska AF, Sikkel MB, Pellegrino L, Jacob J, Frampton AE, Krell J, Coombes RC, Harding SE, Lyon AR, Stebbing J.

Cell Death Dis. 2015 May 7;6:e1754. doi: 10.1038/cddis.2015.89.


Drug testing in the patient: toward personalized cancer treatment.

Coombes RC.

Sci Transl Med. 2015 Apr 22;7(284):284ps10. doi: 10.1126/scitranslmed.aab1214.


Zinc isotopes: a novel approach to biomarkers of breast cancer?

Larner F, Shousha S, Coombes RC.

Biomark Med. 2015;9(4):379-82. doi: 10.2217/bmm.15.8. No abstract available.


Expression of Cancer/Testis genes in ductal carcinoma in situ and benign lesions of the breast.

Caballero OL, Shousha S, Zhao Q, Simpson AJG, Coombes RC, Neville AM.

Oncoscience. 2013 Dec 12;1(1):14-20. eCollection 2014.

Supplemental Content

Loading ...
Support Center